| New and emerging drugs in type 2 diabetes |
|
Ie Byung Park |
|
고려대학교 의과대학 내과학교실 |
| 종설: 새로이 개발되어 사용되기 시작하는 당뇨병 관련약제 |
|
박이병 |
|
|
|
|
|
|
| Abstract |
|
Recent advances in understanding insulin secretion, action and signaling have led to the development of new pharmacological agents. Several new emerging drugs and drug classes for the management of diabetes are under development, including the incretin mimetic agents (exenatide, dipeptidyl peptidase 4 inhibitors, and glucagon-like peptide 1 analogues), the amylin analogue pramlintide, the cannabinoid-1 receptor antagonist rimonabant, the mixed peroxisome proliferator-activated receptor agonists muraglitazar and the inhaled insulin preparation Exubera.
New drugs and technologic advances being made available will help achieve the goals of treating patients with diabetes to all the appropriate metabolic targets. Longer term studies will help providers weigh the benefits, adverse effects, cost, and unknown long-term risks of these medications.(Korean J Med 72:446-450, 2007)
Key Words : Incretin, Exenatide, DPP-IV inhibitor, Pramlintide, Rimonabant, Inhaled insulin |
| Key Words:
Incretin, Exenatide, DPP-IV inhibitor, Pramlintide, Rimonabant, Inhaled insulin |
|
PDF Links
Full text via DOI
Download Citation
